Buyers in Clovis Oncology (CLVS-9.2%) are a scarce commodity. Shares are down on below-average volume in early trade after Goldman Sachs cut its fair value target to $3 (from $13). The stock has …

More Clovis continues selloff, down 9% after Goldman cuts target Videos